Physician profile
Daniel Cunningham
NPI 1831579598
$1,800.71
in general payments reported to CMS, 2019-2025
22 companies · $71.78 in 2025
The $71.78 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.51 · 2021: $178 · 2022: $62.77 · 2023: $479 · 2024: $966 · 2025: $71.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,517.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $287.51 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $200.51 | 2021-2025 | Qulipta |
| Lilly USA, LLC | $169.26 | 2021-2024 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals Lp | $161.82 | 2023-2024 | Farxiga, Airsupra |
| Pfizer INC. | $142.58 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $126.41 | 2024 | Voquezna |
| Exact Sciences Corporation | $87.02 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $68.04 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $67.42 | 2023-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $64.46 | 2022-2024 | Trintellix |
| Theratechnologies INC. | $50.18 | 2022 | |
| Janssen Pharmaceuticals, INC | $46.10 | 2024 | Xarelto |
| Sunovion Pharmaceuticals INC. | $45.42 | 2021 | |
| Lundbeck LLC | $44.86 | 2024 | Rexulti |
| Nevro Corp. | $42.82 | 2023-2024 | Senza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $41.52 | 2024 | Heplisav-B |
| Amgen INC. | $32.84 | 2019-2024 | Prolia, Evenity |
| Alkermes, INC. | $29.85 | 2019 | |
| Idorsia Pharmaceuticals US INC | $29.16 | 2023 | Quviviq |
| Corcept Therapeutics | $23.19 | 2024 | Korlym |
| Merck Sharp & Dohme LLC | $22.91 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Orexo US, INC. | $16.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.